National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 3) (PB 21 of 2020) (Cth)

PB 21 of 2020

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 3)

National Health Act 1953

___________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated         30 March 2020

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2020 (No. 3).

(2)This Instrument may also be cited as PB 21 of 2020.

1. Commencement

This Instrument commences on 1 April 2020.

1. Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1       Amendments

1. Schedule 1, after entry for Dapsone in the form Tablet 100 mg  

insert:

Darunavir with cobicistat, emtricitabine and tenofovir alafenamide Tablet containing darunavir 800 mg with cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg 20 60 5